Last reviewed · How we verify

BOW015 — Competitive Intelligence Brief

BOW015 (BOW015) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline.

phase 3 Small molecule Live · refreshed every 30 min

Target snapshot

BOW015 (BOW015) — Epirus Biopharmaceuticals (Switzerland) GmbH. BOW015 is a biosimilar of a biologic therapeutic targeting a specific disease pathway, designed to provide equivalent efficacy and safety to its reference product.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
BOW015 TARGET BOW015 Epirus Biopharmaceuticals (Switzerland) GmbH phase 3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BOW015 — Competitive Intelligence Brief. https://druglandscape.com/ci/bow015. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: